🇺🇸 Metoprolol succinate sustained-release tablet in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 1 report (10%)
  2. Back Pain — 1 report (10%)
  3. Cough — 1 report (10%)
  4. Drug Dose Omission — 1 report (10%)
  5. Drug Ineffective — 1 report (10%)
  6. Eructation — 1 report (10%)
  7. Fall — 1 report (10%)
  8. Fatigue — 1 report (10%)
  9. Femur Fracture — 1 report (10%)
  10. Gout — 1 report (10%)

Source database →

Metoprolol succinate sustained-release tablet in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Metoprolol succinate sustained-release tablet approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Metoprolol succinate sustained-release tablet in United States?

Sumitomo Pharma (Suzhou) Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.